Sector News

Siemens begins shipping coronavirus antibody tests with goal of 50M per month

May 28, 2020
Life sciences

While aiming to double its manufacturing capacity to more than 50 million blood tests per month, Siemens Healthineers has begun shipping its COVID-19 serology kits internationally, for use on about 20,000 analyzer systems installed worldwide.

The company recently received a CE mark for its IgM and IgG antibody test, designed to run on its high-throughput Advia Centaur and Atellica systems—the latter capable of running up to 440 tests per hour. The kit is currently being reviewed by the FDA for emergency use in the U.S.

Siemens plans to increase production at its sites in Walpole, Massachusetts, and Newark, Delaware, and said it expects to hit the 50-million test target in June.

The company also aims to ship more than 2.5 million molecular, PCR-based coronavirus tests each month, which received an FDA authorization early this month and a CE mark in late April. According to analysts at Bernstein, the company has already sold 500,000 tests in Europe.

Siemens described its total antibody test’s performance as 100% sensitivity and 99.8% specificity—including in detecting the neutralizing antibodies that connect to and block the novel coronavirus’s spike protein, which allows it to enter and infect cells.

“Not all antibody tests are created equal,” Siemens’ president of laboratory diagnostics, Deepak Nath, said in a statement. “A high-quality test that targets the right protein and is highly scalable is essential for antibody testing to help ensure we effectively manage the threat of COVID-19.”

“Siemens Healthineers sought to provide a highly accurate antibody test that could reach millions of people to address the current need for identifying immune response, and also for delivering long-term value as we look toward immunity and vaccination,” Nath added.

The company is also developing similar tests for its Dimension Vista and EXL systems, as well as a specific IgG test to meet different clinical needs.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.